36 results about "Pain responses" patented technology

A method for delivery of an agent to a cell using electroporation is disclosed. The method includes positioning a first electrode and a second electrode such that an electrical signal passed between the first electrode and the second electrode passes through the cell. The method also includes passing an electrical signal between the first electrode and the second electrode, the electrical signal having a frequency greater than about 10 kHz. In one embodiment of the method, the electrical signal has a bipolar waveform. In another embodiment of the method, the electrodes are positioned at a treatment site, e.g., a tumor, for in vivo delivery of an agent.

A fluid delivery device is provided for delivering fluid to a target site such as an intervertebral disc during discography. The fluid delivery device includes pressure and volume sensors to determine the pressure and the volume of the fluid delivered to the intervertebral disc. The fluid delivery device is hand-held during use and includes a syringe assembly having a plunger with threads that enables controlled discharge of the fluid from the fluid delivery device by rotating the plunger in a housing of the fluid delivery device. The fluid delivery device may also include a communication module to wirelessly transfer data to an external device outside of a sterile field, while the fluid delivery device is in the sterile field. The fluid delivery device may also include a physiological sensor to monitor involuntary pain responses based on changing physiological parameters such as increases in body temperature or blood pressure.

A method concerning measurements by using an electrode array comprising three electrodes for central nervous system (CNS) monitoring from the forehead of a patient's head. A first electrode of said three electrodes is positioned between the eyebrows or immediately above the eyebrows of the patient. A third electrode of said three electrodes is positioned apart from the first electrode on the hairless fronto-lateral area of the forehead the patient. A second electrode is positioned between the first and the third electrodes on the forehead of the patient.

A focus card evokes a neurological response in a user to dampen the user's response to a negative stimulus. A focus card has a first face comprising visual graphics such as lenticular graphics, and a second face comprising indicia pertaining to the visual graphics. Indicia are configured for a target population, and can include novel questions, tasks or directions. A parent or other untrained individual can direct a patient as indicated by the indicia. A single focus card can have indicia for several target populations. A focus card can be used in combination with an analgesia means to further reduce a patient's pain response. By focusing the patient's attention with a focus card, behavior of the patient's anterior cingulate gyrus can be modified to reduce the patient's response to a pain-causing stimulus. It can also be used to reduce agitation, anxiety or distress outside of a medical environment.

A method is described for predicting a pain response in a subject suffering from cancer-induced bone pain (CIBP). Data is collected from the subject by querying the subject on personality and/or health traits, and/or performing one or more social learning and/or (bio)physical tests by or on the subject. The data is used in a set of mathematical models to attribute one or more Scoring Factors to the subject. The Scoring Factor is a measure of the propensity of the subject to raise a response to a pain stimulus or a treatment strategy; and/or a measure of the intensity of the response of the subject.

Disclosed in the present invention is the composition for reducing local fat and body weight, and pharmaceuticals and use thereof. The composition contains resveratrol and curcumin extract at a weight ration from 1:30 to 10:1. The composition and pharmaceuticals thereof of the invention can inhibit the growth of fat cells, cause planned apoptosis of fat cells, achieve the effects of reducing fat cells, and reducing local fat deposition and body weight without causing inflammations or necrosis of surrounding cells or tissues and inflammations or pain reactions of surrounding tissues, thereby avoiding the problems of tissue damage and inflammatory pains caused by liposuction or low invasion fat-dissolving apparatus used in the prior art and the problems such as surrounding tissue inflammations and necrosis infections triggered by cell disruption and necrosis caused by components of a fat-dissolving injection, phosphatidylcholine or sodium deoxycholate.

The present invention provides a method for treating central pain syndrome in a mammal by administering an effective amount of a thalamic anticonvulsant compound. Also provided are methods for inducing centrally generated pain responses in an animal model and for screening and identifying a compound that inhibits T-type calcium channels.

The present invention relates to regulation of cold sensation and pain. More particularly, the present invention is directed to nucleic acids encoding a member of the transient regulatory protein family, CMR1, which is involved in modulation of the perception of cold sensations and pain. The invention further relates to methods for identifying and using agents that modulate cold responses and pain responses stimulated by cold via modulation of CMR1 and CMR1-related signal transduction.

The invention relates to a progesterone water-soluble injection and a preparation method thereof. The progesterone water-soluble injection comprises progesterone, a cyclodextrin derivative solubilizer, an inclusion accelerator and injection water. Sodium citrate and citric acid are taken as the inclusion accelerator, and a complex is formed with cyclodextrin by using the polyhydric structural features of sodium citrate and citric acid, so that the inclusion constant of the complex is improved, the problem that the using amount is excessive when the progesterone water-soluble injection is prepared by using a cyclodextrin derivative as the solubilizer is solved effectively, the using amount is reduced to less than 10%, and the renal toxicity, hemolytic activity and carcinogenicity risk of the cyclodextrin derivative are reduced obviously through such using amount, so that the safety is improved. The pain reaction is relatively lower when the progesterone water-soluble injection is used for injection, the injection is low in irritation, unlikely to be allergic and high in adaptability for long-time use of a patient, and relative to clinically frequently-used progesterone oil-soluble injection in the present stage, the injection has the advantages of dosage form.

The invention discloses application of mastic and myrrh in preparing medicine for preventing and treating nerve pathological pain diseases. Based on the existing pharmacological activity of mastic and myrrh, new clinical effects of mastic and myrrh are screened through deep research via a large quantity of experiments. According to the application, an animal model of nerve pathological chronic pain caused by ligation of the sciatic nerve is used for researching the suppression effect of mastic-myrrh aqueous extract on the pain sense of mice, and experiment results show that after the model for ligation of the sciatic nerve is implemented for 7 days, obvious pain reactions of mice can be caused, while the pain reactions of mice can be remarkably suppressed through oral administration of the mastic-myrrh aqueous extract. The mastic-myrrh aqueous extract provided in the application can be prepared into high-efficiency and low-toxicity treatment medicine for preventing and treating nerve pathological pain, has significant economic value and is worthy of application and popularization.

The invention relates to application of ginkgolic acid in pain alleviation. The ginkgolic acid comprises ginkgo acid, ginkgol, ginkgo diphenol and the like, and can be obtained from an extract of leaves, fruits, testa, rhizomes and the like of ginkgo by a chemical separation method. The pain comprises nerve pain, bone pain, muscle pain, tendon ligament pain, cancer pain and the like. A medicament, a medical instrument, a cosmetic or a disinfectant containing the ginkgolic acid and having a purpose of alleviating pain contains 0.001 to 80 weight percent of ginkgolic acid and pharmaceutically common external preparation matrix or acceptable carrier; and the preparation is any one of pharmaceutical external formulations. Pharmacological experimental research shows that the ginkgolic acid has an obvious effect of improving pain threshold on pain response caused by physical, chemical and cancerous stimulus. Clinical trials show that the ginkgolic acid has a remarkable alleviating effect on various pains and is predominant in curative effect, the effective rate reaches over 95 percent, and the ginkgolic acid is safe in use and does not have side effect.

A device for evoking a temporal summation of pain in a subject. The device comprises a stimulation element (SE) arranged generating a physical stimulation on a skin surface area of at least 20 cm² according to a control signal (CS), where the stimulation (PS) evokes pain in the subject. A processor (PR) generates the control signal (CS) to the stimulation element (SE) so as to provide a repetitive stimulation pattern comprising at least repetitions of: a)applying stimulation for a period (SP) of 0.5-120 seconds, b)stopping stimulation for a period (TP) of 0.5-20 seconds. Preferred periods are 1-3 seconds for both stimulation and intermediate stopping periods. The stimulation element may include an inflatable tourniquet arranged for providing a compressional stimulation of an arm or a leg. However, other types of stimulation elements may be used such as electric, heating, mechanical stimulation or the like may be used. The device is suited for providing a measure of temporal summation in a subject with different intensities, and this measure can be used for determining if the subject suffers from central nervous sensitization which is an important diagnosis with respect to effective analgesic treatment. In some embodiments, the device is arranged to collect pain responses during the stimulation and to calculate a measure of temporal summation of the subject accordingly, e.g. in the form of a rate of pain change (VAS) versus time (T).

The invention relates to progesterone suspending injection and a preparation method thereof. The progesterone suspending injection comprises progesterone, SBA-15, povidone K15 and injection water. According to the invention, under the effect of physical mechanical force, the well-organized crystal structure of the progesterone is damaged but is not suffered from chemical degradation and SBA-15 and progesterone molecule are interacted through hydrogen bond, so that the amorphous progesterone molecule is loaded onto a nanometer structure duct, can be attached to the SBA-15 loading a large quantity of drug molecules and can be maintained under amorphous state; the amorphous progesterone molecule reacts with the povidone K15 through the hydrogen bond, so that the amorphous state is more stable and a certain suspending assisting function is achieved; the technical problems that the progesterone is difficult to dissolve in water, the oil-soluble progesterone injection brings a strong injection pain response and a conventional solubilizing method is not suitable for preparing the progesterone into the injection can be solved; and the progesterone is developed into the injection with stable nature and without pain response in the injection process.

The invention relates to the technical field of medicines, in particular to application of JQ1 or a derivative of the JQ1 in preparation of analgesic drugs. A test result shows that the BRD4 (bromodomain-containing protein 4) inhibitor JQ1 can effectively relieve acute inflammatory pain induced by formalin, and the expression lies in that the duration time of the pain response of mice is obviouslyshortened after JQ1 pretreatment. Experiments prove that the bromodomain-containing protein 4 inhibitor JQ1 has an obvious analgesic effect and can be used for preparation of the analgesic drugs.

The invention provides application of melatonin to preparation of a medicine for treating autoimmune prostatitis and the medicine for treating the autoimmune prostatitis, and belongs to the technical field of medicine application. According to the invention, by enhancing a Sirt1 pathway and inhibiting the NLRP3 inflammasome, the inflammatory change and pain response of prostate tissue and the content of inflammatory cytokines in peripheral blood are reduced. According to the invention, an autoimmune prostatitis mouse model is taken as a test object, and research finds that the melatonin obviously reduces the inflammatory change and pain response of the prostate tissue and the content of inflammatory cytokines in the peripheral blood by enhancing the Sirt1 pathway and inhibiting the NLRP3 inflammasome, namely that the melatonin inhibits the expression of the NLRP3 inflammasome through Sirt1 dependency to reduce prostatitis, and the melatonin is feasible and effective for treating prostatitis.

A system for administering pain-free injections includes an electric current source having at least two electrodes attached adjacent an injection site, the electric current source producing a variable numbness pattern and providing a frame of reference for identifying a plurality of sub-areas of the injection site; and a probe applied to the plurality of sub-areas of the injection site for pain-response testing, wherein one or more areas of numbness in the variable numbness pattern are identifiable according to the plurality of sub-areas of the injection site. A fence may be removably applied to the injection site and provide a frame of reference for identifying a plurality of sub-areas of the injection site, and may aid in identifying one or more areas of numbness in the variable numbness pattern. The fence may be removably applied to the injection site via a belt or manual pressure.

The use of a glial attenuator, such as ibudilast (3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine), to prevent the negative consequences of glial priming is described. In particular, the present invention is directed to a method of treating a subject with ibudilast to prevent amplified pain responses to inflammation or injury as a result of glial priming following an initial glial activating event.

The invention discloses application of total alkaloids of cynanchum komarovii in preparation of anti-inflammatory and analgesic drugs. The research finds that the total alkaloids of cynanchum komarovii can prolong the thermal withdrawal latency period of a mouse in a thermal stabbing pain experiment, shorten the paw licking time of the mouse in a formalin pain experiment; and prolong the pain latency period of the mouse in an acetic acid writhing experiment, and reduce the writhing frequency, thereby effectively alleviating the pain response of the mouse. In addition, the total alkaloids of cynanchum komarovii can prolong the thermal withdrawal latency period and increase the mechanical withdrawal threshold of CIA rats, which indicates that the total alkaloids of cynanchum komarovii also have a mitigative effect on chronic inflammatory pain. Meanwhile, the total alkaloids of cynanchum komarovii can remarkably inhibit expression of inflammatory factors such as GFAP, NMDAR2B, TNF-a, IL-6 and IL-17, so that the total alkaloids of cynanchum komarovii can be used as a main component of anti-inflammatory and analgesic drugs, thus providing a new way for research and development of new drugs.

The invention discloses the application of 2-methyl-5-acetyl-4-furangerma-1(10)-alkene-6-ketone in preparing analgesics. The application is characterized in that on the basis of present pharmacological activity, the analgesic effect of 2-methyl-5-acetyl-4-furangerma-1(10)-alkene-6-ketone is evaluated through a large number of experiments combined with various mouse pain models. An acute pain modelcaused by harmful heat and mechanical stimulation and a chronic pain mouse model caused by complete Freund's adjuvant are adopted for researching a inhibiting effect of the compound on pains, and anexperiment result shows that the compound is capable of remarkably inhibiting various pain reactions of mouse dose-dependently. The 2-methyl-5-acetyl-4-furangerma-1(10)-alkene-6-ketone provided by theinvention can be prepared into high-efficient and low-toxicity protective drugs for preventing and treating various chronic pains, has important economic value and is worthy of promotion and application.